英国卵巢癌筛查协作试验中绝经后女性连续子宫内膜厚度与非子宫内膜激素依赖性癌症风险
该研究嵌套于英国卵巢癌筛查协作试验超声组,纳入38105名50-74岁绝经后女性,随访中1398例乳腺癌、222例卵巢癌、381例肺癌等。采用联合模型分析发现,子宫内膜厚度倍增显著增加乳腺癌(HR 1.21)、卵巢癌(HR 1.39)和肺癌(HR 1.25)风险,其余六种癌症无显著关联。
要点
- 子宫内膜厚度倍增与乳腺癌风险升高相关(HR 1.21,95%CI 1.09-1.36)。
- 子宫内膜厚度倍增与卵巢癌风险升高相关(HR 1.39,95%CI 1.06-1.82)。
- 子宫内膜厚度倍增与肺癌风险升高相关(HR 1.25,95%CI 1.02-1.54)。
核心结论
- 经阴道超声发现子宫内膜厚或增厚的绝经后女性,乳腺癌、卵巢癌和肺癌风险增加。
研究设计与样本
- 嵌套于英国卵巢癌筛查协作试验(UKCTOCS)超声组的队列研究。
- 50639名50-74岁绝经后女性接受年度经阴道超声检查,其中38105名有有效子宫内膜厚度测量、无子宫切除史且协变量数据完整者纳入分析。
- 通过国家癌症登记处链接随访。
- 采用联合模型评估纵向生物标志物与时间-事件数据,Cox模型评估基线子宫内膜厚度与癌症关联。
- 所有模型均调整当前激素替代治疗使用、体重指数、末次月经年龄、产次和口服避孕药使用。
主要发现
- 38105名纳入女性共获得267567次有效子宫内膜厚度测量(中位数8,四分位距5-9)。
- 中位随访10.9年,合计407838随访年,登记1398例乳腺癌、351例子宫内膜癌、381例肺癌、495例结直肠癌、222例卵巢癌、94例胰腺癌、79例膀胱癌、62例胃癌、38例肝癌和52例非霍奇金淋巴瘤。
- 联合模型显示,子宫内膜厚度倍增显著增加乳腺癌风险(HR 1.21,95%CI 1.09-1.36,P=0.001)。
- 联合模型显示,子宫内膜厚度倍增显著增加卵巢癌风险(HR 1.39,95%CI 1.06-1.82,P=0.018)。
- 联合模型显示,子宫内膜厚度倍增显著增加肺癌风险(HR 1.25,95%CI 1.02-1.54,P=0.036);其余六种癌症与子宫内膜厚度无统计学显著关联。
临床怎么用
- 作者认为,临床医生应知晓经阴道超声所见的子宫内膜厚或增厚与乳腺癌、卵巢癌和肺癌风险增加相关,因为经阴道超声是常见检查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Estrogen is a well-established risk factor for various cancers. It causes endometrial proliferation, which is assessed routinely as endometrial thickness (ET) using transvaginal ultrasound (TVS). Only one previous study, restricted to endometrial and breast cancer, has considered ET and the risk of non-endometrial cancer. The aim of this study was to explore the association between baseline and serial ET measurements and nine non-endometrial hormone-sensitive cancers, in postmenopausal women, using contemporary statistical methodology that attempts to minimize the biases typical of endogenous serial data. METHODS: This was a cohort study nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). In the ultrasound arm of UKCTOCS, 50639 postmenopausal women, aged 50-74, underwent annual TVS examination, of whom 38 105 had a valid ET measurement, no prior hysterectomy and complete covariate data, and were included in this study. All women were followed up through linkage to national cancer registries. The effect of ET on the risk of six estrogen-dependent cancers (breast, ovarian, colorectal, bladder, lung and pancreatic) was assessed using joint models for longitudinal biomarker and time-to-event data, and Cox models were used to assess the association between baseline ET measurement and these six cancers in addition to liver cancer, gastric cancer and non-Hodgkin's lymphoma (NHL). All models were adjusted for current hormone-replacement therapy (HRT) use, body mass index, age at last menstrual period, parity and oral contraceptive pill use. RESULTS: The 38 105 included women had a combined total of 267 567 (median, 8; interquartile range, 5-9) valid ET measurements. During a combined total of 407 838 (median, 10.9) years of follow-up, 1398 breast, 351 endometrial, 381 lung, 495 colorectal, 222 ovarian, 94 pancreatic, 79 bladder, 62 gastric, 38 liver cancers and 52 NHLs were registered. Using joint models, a doubling of ET increased significantly the risk of breast (hazard ratio (HR), 1.21; 95% CI, 1.09-1.36; P = 0.001), ovarian (HR, 1.39; 95% CI, 1.06-1.82; P = 0.018) and lung (HR, 1.25; 95% CI, 1.02-1.54; P = 0.036) cancers. There were no statistically significant associations between ET and the remaining six cancers. CONCLUSION: Postmenopausal women with high/increasing ET on TVS are at increased risk of breast, ovarian and lung cancer. It is important that clinicians are aware of these risks, as TVS is a common investigation. © 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Burnell M, Gentry-Maharaj A, Glazer C, et al. Serial endometrial thickness and risk of non-endometrial hormone-dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening. Ultrasound Obstet Gynecol. 2020. PMID: 31614036. doi:10.1002/uog.21894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。